Press Releases

Gamma Biosciences, a life sciences tools platform created by KKR, announced that it has acquired Nanopareil LLC, a South Dakota, US-based company developing next-generation nanofiber membrane products for chromatographic separation in bioproduction. Nanopareil's membrane technology employs a novel, durable nanofiber structure that offers significant performance advantages compared with conventional chromatography resins as well as similar, non-resin-based separation technologies.

Eisai Co., Ltd. and Seikagaku Corporation announced today that the companies have entered into an agreement for the marketing alliance in South Korea for SI-613 (diclofenac conjugated sodium hyaluronate), a therapeutic agent for osteoarthritis discovered by Seikagaku. Eisai and Seikagaku signed an agreement for the co-development and marketing alliance in China of SI-613 on April 1, 2020. Thus, South Korea becomes the second country for the companies to conclude the marketing alliance for SI-

Sema4, a patient-centered health intelligence company, today announced that it has entered into a research agreement with Janssen Research & Development, LLC (Janssen) to optimize oncology clinical trials. Together, Sema4 and Janssen will utilize genomic testing and advanced data analytics to more efficiently and accurately identify patients diagnosed with cancer who may be candidates for oncology clinical trials. Approximately 1.8 million people are expected to be diagnosed wit

Eton Pharmaceuticals, Inc , a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved ALKINDI® SPRINKLE (hydrocortisone) oral granules as replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age. ALKINDI SPRINKLE is the first and only FDA-approved granular hydrocortisone formulation for the treatment of adren

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, and LabCorp®, a leading global life sciences company that is focused on advancing health and guiding patient care decisions, have agreed to a five-year exclusive licensing agreement for GENFIT’s NIS4™ technology to help identify patients with at-risk non-alcoholic steatohepatitis (NASH). As part of the agreement, LabCorp will develop and commercialize

Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that the European Commission has granted a marketing authorization for ZYNRELEF (formerly known as HTX-011) for the treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults. The marketing authorization follows the European Medicines Agency

Ahead of the CPhI Festival of Pharma (5-16 October, 2020) – global pharma’s largest ever virtual gathering – the CPhI Pharma Index[i] shows only Italy and India have improved their score in 2020, with the majority of industry executives looking for new supply chain partners. The Index – an aggregated confidence score across the five main small molecule categories in each of the largest economies – compiles the findings from more than 550 executives and

Syntegon Technology’s Schiedam site is celebrating over half a century of market presence. In October, the company’s Dutch site turns 60. Today a market-leading provider of horizontal flow wrappers, infeed and distribution systems, the current Syntegon Packaging Technology B.V. took up business as Tevopharm, an acronym of Techniek for Voeding and Pharmacie (Technical solutions for food and pharma) in the early 1960s. “We are proud of this long legacy,” Neil Fowell, gen

Gilead Sciences, Inc. and Eisai Co., Ltd. announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted Gilead K.K. (Tokyo, Japan) regulatory approval of Jyseleca (filgotinib 200 mg and 100 mg tablets), a once-daily, oral, JAK1 preferential inhibitor for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies, including the prevention of structural joint damage. Gilead Japan will hold the marketing

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, announced APL-106 (uproleselan) has received Investigational New Drug (IND) approval from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). This approval enables the initiation of a Phase 1 pharmacokinetics (PK) and tolerability study and includes acceptance of a Phase 3 bridging study of APL-106 in combina